Lenalidomide and rituximab in Waldenstrom's macroglobulinemia

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 355-360

  Treon, Steven P ^a,b,c   Soumerai, Jacob D ^a   Branagan, Andrew R ^a   Hunter, Zachary R ^a   Patterson, Christopher J ^a   Loakimidis, Leukothea ^a   Chu, Luis ^d   Musto, Paul ^e   Baron, Ari D ^f   Nunnink, Johannes C ^g   Kash, Joseph J ^h   Terjanian, Terenig O ⁱ   Hyman, Paul M ^j   Nawfel, Elena L ^k   Sharon, David J ^l   Munshi, Nikhil C ^b,c   Anderson, Kenneth C ^b,c  

^a Jerome Lipper Multiple Myeloma center   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Florida Cancer Specialists ^*  (United States)

^e Commonwealth Hematology Oncology ^*  (United States)

^f Pacific Hematology Oncology Associates   (United States)

^g UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^h Edward Hospital and Health Services Cancer Center   (United States)

ⁱ STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^j Hematology Oncology Associates of Western Suffolk PC   (United States)

^k Harold Alfond Center for Cancer Care   (United States)

^l MONMOUTH MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; IMMUNOGLOBULIN M; LENALIDOMIDE; RITUXIMAB;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; ARTICLE; BACKACHE; BLOOD VISCOSITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEMATOCRIT; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; LEUKOPENIA; LIVER FUNCTION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; URINARY URGENCY; VISUAL IMPAIRMENT; WALDENSTROEM MACROGLOBULINEMIA;

AGED; AGED, 80 AND OVER; ANEMIA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; NEUTROPENIA; THALIDOMIDE; THROMBOCYTOPENIA; WALDENSTROM MACROGLOBULINEMIA;

EID: 58849160495     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0862     Document Type: Article

References (22)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopatho-logical definition of Waldenström's macroglobuline-mia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-5.
2. Harris NL, Jaffe ES, Stein H. A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994:84:1361 -92.
3. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia. November 1997. J Clin Oncol 1999:17: 3835-49
4. Treon SP. Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia. Blood 2006;107:3442-6.
5. Leleu X, Soumeria JD, Hunter ZR, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom's macroglobu-linemia treated with nucleoside analogues. J Clin Oncol 2008. In press.
6. Davies FE, Raje N, Hideshima T, et al. Lenalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-6.
7. Janakiraman N, McLaughlin P, White CA, et al. Ritux-imab: correlation between effector cells and clinical activity in NHL. Blood 1998;92:337a.
8. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion: correlations with clinical response. Clin Cancer Res 2004;10:2253-64.
9. Khan KD, Emmanouilides C, Benson DM, et al. A phase 2 study of rituximab in combination interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res 2006:12:7046-53.
10. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom's macroglobulinemia Blood 2008. In press.
11. Treon SP, Hatjiharissi E, Leleu X, et al. Novel agents in the treatment of Waldenstrom's macroglobulinemia. Clin Lymph Myeloma 2007;7:199-206.
12. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003:30:116-20.
13. Kimby E.Treon S, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymph Myeloma 2006:6:380-3
14. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004:15:1481-3.
15. Ghobrial IM. Fonseca R, Greipp PR, et al. Initial immunoglobulin M "flare" after rituximab therapy in patients with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group study. Cancer 2004;101:2593-8.
16. Treon SP, Mitsiades C Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in B-cell malignancies. J Immun other 2001:24:263-71.
17. Dimopoulos MA, Zervas C. Zomas A. et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002:20:2327 - 33.
18. Treon SP. Emmanouilides C, Kimby E. et al Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 2005:16:132-8.
19. Treon SP. Hansen M, Branagan AR, et al Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical responses to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005:23 474 - 81.
20. Hayashi T, HideshimaT, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application Br J Haematol 2005;128:192-203.
21. Koh KR. Janz M. Mapara MY, et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 2005:105:3833-40.
22. Pomalidomide and lenalidomide regulate erythropoeisis and fetal hemoglobin production in human CD34 cells Clin Invest 2008:118:248-58